• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Bayer AG

Bayer AG

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Bayer Plans to Sell Equine-Health Products to Sanofi Unit

    Bayer Plans to Sell Equine-Health Products to Sanofi Unit

  2. Research and Markets: Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014

    Research and Markets: Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014

  3. FDA Grants QIDP Designation to Bayer's Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation

    FDA Grants QIDP Designation to Bayer's Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation

  4. Research and Markets: Global & USA Transdermal Drug Delivery Market to 2017

    Research and Markets: Global & USA Transdermal Drug Delivery Market to 2017

  5. Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 6th Update

    Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 6th Update

  6. Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 3rd Update

    Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 3rd Update

  7. Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 5th Update

    Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 5th Update

  8. Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 4th Update

    Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 4th Update

  9. Research and Markets: Venous Thromboembolism - Pipeline Review, H2 2014

    Research and Markets: Venous Thromboembolism - Pipeline Review, H2 2014

  10. Research and Markets: Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2014

    Research and Markets: Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2014

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.